VA
DSGN icon

Verdad Advisers’s Design Therapeutics DSGN Stock Holding History

Verdad Advisers’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$982K Buy
+92,310
New +$934K 1.11% 24

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Verdad Advisers's DSGN Position: Q1 2026 in Review

Verdad Advisers opened a new position in Design Therapeutics (DSGN) in Q1 2026: 92,310 shares worth $982K. The stake represents 1.11% of the portfolio and ranks #24 among its holdings.

125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Verdad Advisers held 92,310 shares of Design Therapeutics worth $982K as of Q1 2026.
  • Design Therapeutics was a new Verdad Advisers position in Q1 2026.
  • Design Therapeutics made up 1.11% of Verdad Advisers's portfolio in Q1 2026, its #24 holding.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Verdad Advisers's 13F filing for Q1 2026, filed 15 May 2026.